Aurora Cannabis Inc ACB deserves credit for building industry leading scale and strong margins, but Bank of America thinks the company is burning fast at a concerning pace.
The Analyst
Bank of America's Christopher Carey downgraded Aurora's U.S.-listed stock from Buy to Neutral with a price target lowered from $10 to $8.
The Thesis
Aurora could be considered "among the best" cannabis companies and similar to its peers, Aurora is bleeding out cash, Carey wrote in the note. Aurora's cash position is "less robust" compared to its peers and is on track to turn negative as early as the first quarter 2020.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
Aurora faces a large convertible debenture of CA$230 million at a price of CA$13.05 (versus CA$9.68 at the time of the analyst's note), which is "well out of the money" and may need to be settled in cash. Aurora's cash burn stems from its investments in four production facilities that consists of around 1.35 million new square feet of facility space across Canada, Denmark and Portugal. Based on current estimates, Aurora will have a "paltry" CA$70 million of cash on hand in the first quarter, but the out-of-money convert would bring the cash position in the red.
Ultimately, Aurora's premier status in the cannabis space should help it secure any necessary financing gaps, which implies concerns of solvency are unjustified. It's "less ideal" to seek out new capital from a defensive position compared to other companies who raise capital for "larger untapped growth opportunities," including U.S. CBD-focused companies.
Price Action
Shares of Aurora Cannabis were trading lower by more than 6.6% at $6.92 Thursday morning.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.